Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: Preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia
Autore:
Stripecke, R; Skelton, DC; Pattengale, PK; Shimada, H; Kohn, DB;
Indirizzi:
Childrens Hosp Los Angeles, Div Res Immunol BMT, Los Angeles, CA 90027 USAChildrens Hosp Los Angeles Los Angeles CA USA 90027 Angeles, CA 90027 USA Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA Univ So Calif Los Angeles CA USA 90033 Immunol, Los Angeles, CA 90033 USA Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA 90027 USA Childrens Hosp Los Angeles Los Angeles CA USA 90027 Angeles, CA 90027 USA
Titolo Testata:
HUMAN GENE THERAPY
fascicolo: 13, volume: 10, anno: 1999,
pagine: 2109 - 2122
SICI:
1043-0342(19990901)10:13<2109:COCAGC>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYTOTOXIC T-LYMPHOCYTES; EPIDERMAL LANGERHANS CELLS; POTENT ANTITUMOR IMMUNITY; HLA CLASS-I; DENDRITIC CELLS; BCR-ABL; MYELOID-LEUKEMIA; GM-CSF; COSTIMULATORY MOLECULES; FUSION PROTEINS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
52
Recensione:
Indirizzi per estratti:
Indirizzo: Kohn, DB Childrens Hosp Los Angeles, Div Res Immunol BMT, 4650 Sunset Blvd,Mailstop62, Los Angeles, CA 90027 USA Childrens Hosp Los Angeles 4650 Sunset Blvd,Mailstop 62 Los Angeles CA USA 90027
Citazione:
R. Stripecke et al., "Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: Preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia", HUM GENE TH, 10(13), 1999, pp. 2109-2122

Abstract

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) isa highly aggressive malignancy caused by the bcr-abl translocation oncogene. To explore alternative treatments for Ph+ ALL we tested gene-modified cell vaccines in the BALB/c-derived BM185 leukemia model. We compared the efficacy of BM185 cell vaccine expressing CD80 alone or in combination with IL-2 or GM-CSF. Mice injected with viable BM185 leukemia cells modified to express CD80 and GM-CSF (BM185/CD80+GM-CSF) showed the highest leukemia rejection rates, Cell vaccines consisting of irradiated BM185/CD80+GM-CSF cells administered subcutaneously stimulated a potent cytotoxic T lymphocyte (CTL) response against parental BM185. Histological examination of the vaccination site showed a large concentration of immune cells, Administration of the BM185/CD80+GM-CSF cell vaccine before intravenous challenge with parentalcells caused strong inhibition of leukemia development. Vaccination after subcutaneous challenge with BM185 cells caused efficient elimination of leukemia promoting 40-60% long-term survival rates. The immunization efficacy of the BM185/CD80+GM-CSF cell vaccine was directly correlated with the percentage of cells expressing the transgenes. In all, this preclinical study shows that leukemia cell vaccines coexpressing CD80 and GM-CSF can potentially be explored for immunotherapy in Ph+ ALL patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 09:34:43